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Background: Curative-intent therapies for hepatocellular carcinoma (HCC) include radiofrequency ablation
(RFA), liver resection (LR), and liver transplantation (LT). Controversy exists in treatment selection for earlystage tumours. We sought to evaluate the oncologic outcomes of patients who received either RFA, LR, or LT
as first-line treatment for solitary HCC ≤ 3 cm in an intention-to-treat analysis.
Materials and methods: All patients with solitary HCC ≤ 3 cm who underwent RFA, LR, or were listed for LT
between Feb-2000 and Nov-2018 were analyzed. Cox regression analysis was then performed to compare
intention-to-treat (ITT) survival by initial treatment allocation and disease-free survival (DFS) by treatment
received in patients eligible for all three treatments.
Results: A total of 119 patients were identified (RFA n = 83; LR n = 25; LT n = 11). The overall intention-to-treat
survival was similar between the three groups. The overall DFS was highest for the LT group. This was signif
icantly higher than RFA (p = 0.02), but not statistically significantly different from LR (p = 0.14). After
multivariable adjustment, ITT survival was similar in the LR and LT groups relative to RFA (LR HR:1.13, 95%CI
0.33–3.82; p = 0.80; LT HR:1.39, 95%CI 0.35–5.44; p = 0.60). On multivariable DFS analysis, only LT was better
relative to RFA (LR HR:0.52, 95%CI 0.26–1.02; p = 0.06; LT HR:0.15, 95%CI 0.03–0.67; p = 0.01). Compared to
LR, LT was associated with a numerically lower hazard on multivariable DFS analysis, though this did not reach
statistical significance (HR 0.30, 95%CI 0.06–1.43; p = 0.13)
Conclusion: For treatment-naïve patients with solitary HCC ≤ 3 cm who are eligible for RFA, LR, and LT, adjusted
ITT survival is equivalent amongst the treatment modalities, however, DFS is better with LR and LT, compared
with RFA. Differences in recurrence between treatment modalities and equipoise in ITT survival provides support
for a future prospective trial in this setting.
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early-stage (≤3 cm) single tumours, as all three treatment modalities
offer favourable results, each with moderate-high evidence [6,7]. Due to
practical and ethical concerns, a randomized trial has not been per
formed for management of these patients. Furthermore, previous studies
have compared at the most two of these available modalities [8–12].
We sought to evaluate the oncologic outcomes of patients who
received either RFA, LR, or LT as first-line treatment for single HCC ≤ 3
cm in an intention-to-treat analysis. The rationale for the solitary HCC
cohort was to limit heterogeneity in prognosis due to potentially varying

1. Introduction
Hepatocellular carcinoma represents the leading cause of cancerrelated deaths in many parts of the world and is estimated to become
the third most common cause of cancer-related deaths by 2040 [1,2].
The incidence rate of HCC in countries with a high sociodemographic
index, such as the United States, has increased since the 1990 [1].
Acceptable first-line treatment for early-stage hepatocellular carci
noma (BCLC-0 [single ≤ 2 cm] or BCLC-A [up to 3 nodules ≤ 3 cm], with
Abbreviations
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preserved liver function and Eastern Cooperative Oncology Group
[ECOG] performance status 0) include radiofrequency ablation (RFA),
liver resection (LR), and liver transplantation (LT) [3–5]. Nonetheless,
controversy exists in the curative-intent treatment selection for
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tumour biology.

Fig. 1. STROBE-compliant diagram of patient inclusion and exclusion.
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2. Material and methods

transplantation. The ITT analysis thus accounted for patients who were
placed on the waitlist but dropped out.

This study was approved by our institutional Research Ethics Board
(REB #16-5285), and a waiver of informed consent was obtained. This
study complies with the Strengthening the Reporting of Observational
Studies in Epidemiology (STROBE) statement for observational studies
[13]. Moreover, this work has been reported in line with the Strength
ening the Reporting of Cohort Studies in Surgery (STROCSS) criteria
[14].

2.5. Follow-up, survival, and recurrence
After treatment, patients are followed with thoracoabdominal
contrast-enhanced computed tomography (CT) and AFP measurements
in 3-month intervals for the first 2 years, every 6 months in the 3rd and
4th year post-treatment, and yearly thereafter. Patients with cirrhosis
will resume routine 6-month surveillance after 5 years post-treatment. If
a recurrence is suspected, additional imaging studies are obtained,
which include dedicated contrast-enhanced CT, contrast-enhanced ul
trasonography, or magnetic resonance imaging (MRI) [22].

2.1. Study design and population
This is a retrospective cohort study of patients from a single highvolume academic medical center. Adult (≥18 years) patients with soli
tary HCC ≤ 3 cm who underwent either RFA, LR, or were listed for an LT
between Feb-2000, and Nov-2018 were included. The last day of followup was April 5, 2021. The diagnosis of HCC was made according to in
ternational guidelines [15]. The treatment selection was established by
an institutional multidisciplinary board discussion and based on tumour
size, location, liver function, patient comorbidities, and functional sta
tus. Further details of the treatment selection process are outlined
elsewhere [6]. Patients were excluded if they had pathology other than
HCC, had received previous treatments, or were not eligible for all of the
three treatments (Fig. 1). In the study period, the treatment decision was
based on consensus from a multidisciplinary discussion. Patients
considered eligible for RFA were those with single HCC under 3 cm,
acceptable liver function (Child-Pugh A or B), absence of encephalopa
thy, and a tumor being amenable to an imaging-guided procedure [6].
Furthermore, typically patients with advanced cirrhosis and portal hy
pertension were not considered for LR unless a laparoscopic approach
and minor hepatic resection could be performed for treatment [16].
Moreover, with regards to LT, contraindications included an AFP level
>1000, age greater than 70, and medical comorbidities that would
preclude transplantation [6]. To ensure inclusion of patients theoreti
cally eligible for either RFA, LR, or LT we excluded patients with a
platelet count <100,000 before treatment [17], AFP level >1000 before
treatment [18], age >70 years [6], Child-Pugh score C19, esophageal
varices grade greater than 2 [19], Model for End-stage Liver Disease
(MELD) score before treatment exceeding 15 [20], presence of ascites or
encephalopathy pretreatment [21], and a spleen size exceeding 12 cm
[17].

2.6. Statistical analysis
Descriptive data were expressed as medians and interquartile ranges
(IQR) and compared using Mann-Whitney U tests. Categorical variables
were expressed using numbers and percentages and compared using chisquare and Fischer exact tests. ITT survival was estimated using the
Kaplan-Meier method stratified by RFA, LR, or LT listing. Patients were
censored at death or last known follow-up. DFS was defined as the time
after treatment during which the patient was alive and free of disease.
For DFS, patients were censored at recurrence, death, or loss to follow
up. DFS was estimated using the Kaplan-Meier method stratified by
treatment using log-rank tests. For all survival analyses, pairwise com
parisons using Benjamini-Hochberg correction were performed. Cox
proportional hazards regression models were used for adjustment of a
priori selected clinically relevant confounding variables including MELD
score, tumor size, patient age, AFP level, year of treatment, and tumor
location.
All two-sided p-values less than 0.05 were considered statistically
significant. Statistical analyses were performed using R (version 4.1.1
2021, R Core Team R: A language and environment for statistical
computing. R Foundation for Statistical Computing, Vienna, Austria.
http://www.R-project.org/).
3. Results
3.1. Study population
A total of 119 patients met inclusion criteria (RFA n = 83, LR = 25,
LT n = 11; Fig. 1). The dropout rate for patients listed for LT was 27% (n
= 3). Reasons for dropout included death (n = 1), disease control with
bridging therapy (n = 1), and patient request (n = 1). The median
follow-up of the cohort was 6.6 years (IQR 3.1–10.5). There was no
difference in the duration of median follow-up based on the treatment
received: RFA 6.8 years (IQR 3.5–10.3), LR 4.5 years (IQR 2.2–7.4), and
LT 8.4 years (IQR 3.7–12.9) (p = 0.17). Patients were similar in gender,
age, etiology of liver disease, MELD score, Child-Pugh score, and AFP.
Tumor size was highest in the LR group (Table 1). The clinical decisionmaking for the LT listed patients is shown in Table S1.

2.2. Covariates
We recorded gender (male or female); age; liver disease etiology;
biologic MELD score; and pre-treatment platelet count (x1000), ChildPugh score (A or B), and alpha-fetoprotein (AFP) (ng/dL). We defined
pre-treatment as the most recent measurement (no longer than 6
months) before RFA, LR, or LT listing. Tumours were categorized as deep
(≥2 cm or would require a resection greater than a wedge) or superficial
(<2 cm or could be performed with a wedge resection) depending on the
depth from the liver surface assessed on cross-sectional imaging
(computed tomography or magnetic resonance imaging) on axial,
sagittal and coronal sections.

3.2. Intention-to-treat survival

2.3. Outcome measures

The median survival was not reached in the RFA group, was 13.3
years in the LR group, and was not reached in the LT group. The un
adjusted ITT survival was similar among the groups: (%, 95% CI) 1-year
RFA 100% (100-100), LR 100% (100-100), LT 90.9% (75.4–100) (p <
0.01), 5-year RFA 89.2% (82.4–96.6), LR 94.4% (84.4–100), LT 81.8%
(61.9–100) (p = 0.43), 10-year RFA 80.1% (70.1–91.6), LR 85.9%
(69.0–100), LT 71.6% (48.8–100) (p = 0.52), 15-year RFA 70.3%
(56.0–88.2), LR 42.9% (15.7–100), LT 71.6% (48.8–100) (p = 0.93)
(Fig. 2). Further, on multivariable analysis for ITT survival all modalities
had an equivalent mortality hazard (ref: RFA, LR HR:1.13, 95%CI
0.33–3.82; p = 0.80 and LT HR 1.39, 95%CI 0.35–5.44; p = 0.60)

The study’s primary outcome was intention-to-treat (ITT) overall
survival and disease-free survival (DFS).
2.4. Intention-to-treat survival
ITT was evaluated from the first treatment modality that was
selected for curative intent. In the case of.
RFA and LR this was recorded as the time of the treatment. In the
case of LT, the intention-to-treat was recorded at the time of listing for
3
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Table 1
Patient and tumor characteristics.

Male, n (%)
Age, median (IQR)
Etiology, n (%)
ETOH
HBV
HCV
NASH
Other
MELD score, median
(IQR)
Tumor size (cm), median
(IQR)
Platelet count (x1000),
median (IQR)
Child-Pugh score, n (%)
A
B
AFP (ng/dL), median
(IQR)
Tumor location, n (%)
Superficial
Deep

RFA (N =
83)

LR (N = 25)

LT (N = 11)

pvalue

66 (80%)
60 (56, 66)

21 (84%)
64 (55, 67)

8 (73%)
60 (52, 65)

0.73
0.78

6 (7%)
46 (55%)
22 (27%)
4 (5%)
5 (6%)
7 (6, 8)

0 (0%)
17 (68%)
7 (28%)
0 (0.0%)
0 (0%)
7 (6, 8)

1 (9%)
5 (46%)
4 (36%)
0 (0%)
0 (0%)
7 (7, 9)

2.0 (1.6,
2.5)
154 (123,
192)

2.5 (2.3,
2.8)
158 (137,
217)

1.7 (1.4,
2.1)
128 (124,
145)

79 (95%)
4 (5%)
6 (4, 42)

25 (100%)
0 (0%)
7 (4, 92)

11 (100%)
0 (0%)
9 (5, 146)

47 (57%)
36 (43%)

14 (56%)
11 (44%)

6 (55%)
5 (46%)

Table 2
Effect of treatment (RFA, LR, or LT) on intention-to-treat survival and diseasefree survival.
Reference: RFA
Outcome
Intention-to-treat survivala
LR
LT (listing)
a
Disease-free survival
LR
LT (transplant)

0.15

HR (95% CI)

p-value

1.13 (0.33–3.82)
1.39 (0.35–5.44)

0.80
0.60

0.52 (0.26–1.02)
0.15 (0.03–0.67)

0.06
0.01

Abbreviations: CI: confidence interval, HR: hazard ratio, LR: liver resection, LT:
liver transplant, RFA: radiofrequency ablation.
a
Adjusted for a) patient characteristics: Model for End-Stage Liver Disease
(MELD), age, b) tumor characteristics: tumor size, alpha-fetoprotein (AFP)
tumor location and temporal trends: year of treatment.

0.002
0.08
0.41
0.50
0.99

Abbreviations: AFP: alpha-fetoprotein, ETOH: alcohol-related liver disease,
HBV: hepatitis B virus, HCV: hepatitis C virus, IQR: interquartile range, LR: liver
resection, LT: liver transplant, MELD: Model for End-stage Liver Disease, NASH:
non-alcoholic steatohepatitis, RFA: radiofrequency ablation.

Fig. 3. DFS overall cohort.

hazard of DFS, whereas the DFS hazard was better in the LT group (LR
HR:0.52, 95% CI 0.26–1.02; p = 0.06; LT HR:0.15, 95% CI 0.03–0.67; p
= 0.01). Though numerically lower, but not reaching statistical signif
icance, LT was associated with a better DFS than LR (ref: LR, LT HR:0.30,
95% CI 0.06–1.43; p = 0.13) (Table 2).
4. Discussion
The oncologic outcomes of the various treatment strategies for soli
tary HCC ≤ 3 cm are distinct. ITT survival is similar between the three
modalities, however, adjusted DFS is similar in LR and LT, but better
relative to RFA. These findings may offer impetus for future randomized
prospective trials. In the interim, the differences in DFS can be factored
into individualized treatment selection based on provider experience, as
well as individual patient characteristics, wishes, and expectations.
RFA, LR, and LT are viable therapeutic options for very early and
early-stage HCC [15,23]. Nonetheless, selecting the treatment modality
of choice for these patients takes into account tumour burden, degree of
cirrhosis, hepatic function, as well as the patients’ functional status.
Additionally, any clinical decision must balance best evidence-based
medicine practices with patient values and preferences as well as clin
ical expertise. Staging systems, such as the BCLC, can help inform clin
ical decision-making, but cannot substitute for integration of all these
factors, particularly given the geographic heterogeneity leading to
notable variability in the clinical management of HCC [24]. Our findings
share concordance with previous work identifying a therapeutic

Fig. 2. Intention-to-treat survival.

(Table 2).
3.3. Disease-free survival
DFS was better overall in LT compared with RFA (p = 0.02), but not
statistically significantly different than LR (p = 0.14) (Fig. 3). LR had
DFS that was not statistically significantly different from the RFA group
(p = 0.07). The median DFS was 2.1 years in the RFA group, 13.4 years
in the LR group, and not reached in the LT group. The unadjusted DFS
for 1-, 5-, and 10-year were: (%, 95% CI) 1-year RFA 72.3% (63.3–82.6),
LR 82.9% (69.0–99.7), LT 87.5% (67.3–100) (p = 0.36), 5-year RFA
38.1% (28.7–50.4), LR 58.6% (40.9–84.1), LT 87.5% (67.3–100) (p =
0.03), and 10-year RFA 22.8% (13.6–38.4), LR 50.2% (31.4–80.4), and
LT 75.0% (50.3–100) (p = 0.02). On multivariable analysis, relative to
RFA, LR was associated with a non-statistically significantly different
4
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hierarchy, in order of survival benefit especially regarding DFS: LT, LR,
ablation, intra-arterial therapies, systemic therapy, and best supportive
care [25]. Nonetheless, a similar ITT survival was noted for each of the
treatment modalities in our study. The difference may be in part to the
outcome selected (ITT survival) as well as the specific solitary HCC ≤ 3
cm subgroup of patients.
The debate of LT versus LR currently only exists for the subgroup of
patients with early-stage HCC – unifocal lesion < ~5 cm and those with
well-compensated cirrhosis without portal hypertension [5,8]. Both
treatments have been proven to offer long-term survival in well-selected
patients. Shah et al. from UHN and the University of Toronto assessed a
cohort of 347 patients receiving LR (n = 174) and LT (n = 173) between
1995 and 2005 [9]. The overall survival (from LR or LT listing),
analyzed with an intention-to-treat principle, was equivalent between
the two groups (1-,3-,5- year LR 89%, 75%, 56% vs. LT 90%, 70%, 64%;
p = 0.84) [9]. The group also identified that a prolonged (>4 month)
waitlist time portended a higher risk of death (OR 2.5, 95% CI 1.3–5; p
= 0.007), and concluded that unless waitlist time for an LT is short (<4
months), either treatment option (LR or LT) can be considered in pa
tients with early HCC (defined as within Milan criteria) and adequate
hepatic reserve [9]. With regards to recurrence, LR has been associated
with a lower recurrence-free survival than LT, with 5-year recurrence
exceeding 50% following LR compared to 10–20% after LT [5,26,27].
However, due to the scarcity of organs available for transplantation as
well as associated wait times and high costs associated with LT, both LR
and RFA have become the preferred options for first-line management in
eligible patients. Additionally, in certain jurisdictions, including the
United Network for Organ Sharing (UNOS), patients with T1 tumours (1
lesion < 2 cm) are not eligible for priority listing for LT, mostly sec
ondary to a low risk of dropout while on the waitlist and chance for HCC
misdiagnosis [28]. This has led to two clinical practices; one is to
immediately treat these tumours with locoregional therapies (typically
RFA) [29]. An alternative strategy is to wait, without performing any
locoregional treatment, until the tumour progresses to a T2 (one lesion
2–5 cm or 2-3 lesions ≤ 3 cm) to achieve eligibility for listing, with
MELD exception points. Predictors of rapid progression included His
panic ethnicity and alcohol-related cirrhosis [28]. Patients with a high
risk for waitlist dropout had AFP ≥500 ng/mL and accelerated tumour
progression, and are those who may rather benefit from early locore
gional therapy [28].
Locoregional tumour therapies, such as radiofrequency ablation,
afford high tumour response and acceptable survival, but with high
recurrence rates. Rossi et al. evaluated 706 patients with Child-Pugh A
and B8 cirrhosis with 859 HCC lesions ≤3.5 cm [30]. The cumulative
incidence of the first recurrence at 3- and 5-years was 70.8% and 81.7%,
respectively. The 3- and 5- year OS (after repeated RFAs) was 67.0% and
40.1%, respectively. Despite the high recurrence, RFA is safe and
effective in HCC disease control in cirrhotic patients and offers the
ability for treatment repetition in the case of intrahepatic recurrence
[30]. In a systematic review and meta-analysis comparing RFA and LR,
Xu et al. showed that RFA is associated with lower complications and
shorter hospitalization [11]. Compared to LR, RFA had a higher recur
rence rate but with similar OS. Based on a trial sequential analysis, over
10,000 patients would be needed to prove a significant difference in
3-year survival between these two treatment modalities [11]. Resection
outcomes are also sensitive to liver function. Chong et al. from Hong
Kong evaluated the survival of patients with HCC who received either LR
or microwave ablation and the utility of the Albumin-Bilirubin (ALBI)
[31] score in selecting patients for treatments. In their retrospective
analysis of 442 patients (LR n = 379, MWA n = 63), 63 pairs of patients
were propensity matched on demographic and clinicopathologic vari
ables [32]. Patients who underwent LR had a better OS and DFS if the
ALBI grade was 1 (3-year survival LR 82.6% vs. MWA 72.3%; p = 0.19)
whereas MWA had a better OS (3-year survival LR 54.9% vs. 71.5%; p =
0.03) with similar DFS in patients with ALBI scores of 2 or 3 [32].
Consequently, the group proposed that ALBI grade, as an assessment of

liver function, be incorporated in the decision-making process for these
treatment modalities [32]. Moreover, ablation outcomes are sensitive to
tumour size, as demonstrated by Kutlu et al. in an analysis of the SEER
database between 2004 and 2013, where no difference was noted in
survival for LR vs. RFA if HCC ≤ 3 cm. In contrast, LR was superior once
tumours exceeded three cm [7]. In a cost-effectiveness analysis
comparing LR vs. RFA for early-stage HCC by Cucchetti et al. for very
early HCC in Child-Pugh A patients, RFA achieved similar
quality-adjusted life-years (QALY) at lower costs than LR [33]. For sol
itary lesions between 3 and 5 cm, LR offered better life expectancy and
better cost-effectiveness than RFA [33].
Apart from patient demographic and clinicopathologic variables,
other factors can influence the choice of therapy. These include local
expertise and patient preference (with considerations for procedural
invasiveness, anticipated hospital length of stay, and morbidity and
mortality risks). The role of laparoscopic LR within this context will need
to be explored and is an approach that has been shown to result in lower
blood loss, lower transfusion rates, shorter length of stay, fewer post
operative complications, without differences in the excised surgical
margin, positive margin resection rates, or tumour recurrence [34].
Tumour location, such as proximity to vascular structures, represents a
variable that also needs to be considered during treatment selection. Lee
et al. evaluated LR and RFA as first-line treatment in patients with
perivascular (defined as tumour abutting the first- or second-degree
branches of a portal or hepatic vein) HCC ≤ 3 cm, within BCLC stage
0 or A and found that after propensity matching, extrahepatic recurrence
and OS was better in the LR group compared to the RFA group for pa
tients with periportal HCC, however, extrahepatic recurrence and OS
were similar in patients with perivenous HCC [35]. Besides the size, the
location of the tumour in the liver is a critical factor that dictates the
extent of resection that will be required. In a patient with underlying
liver disease, a deep lesion that may require a more extensive hepatic
resection may be more likely to be recommended to undergo an LT or
RFA. To account for this potential confounding, we included tumour
location in the multivariable adjustments. Anatomic considerations are
also important with regards to locoregional therapies, as insufficient
ablation near vascular structures has also been attributed to a phe
nomenon known as the “heat-sink” effect, whereby during RFA heat loss
occurs into hepatic vessels adjacent to the tumour and influence the
efficacy of ablation [36,37]. It has thus been suggested that both LR and
RFA can be considered as first-line for perivenous HCC, but that LR be
preferred in periportal HCC [35].
This study is limited by its single-institutional and retrospective na
ture, with the potential for misclassification and selection bias. We have
attempted to overcome some of the selection bias by including only
patients who were eligible for all treatments to allow for a clinically
relevant comparison between the groups. Nonetheless, there is potential
for residual and unmeasured confounding. Given the small sample size,
inferences and generalizability are limited, and the potential for type II
error should thus be recognized. Moreover, some patients may have
been recommended to undergo one treatment modality over another
based on factors that have not been objectively accounted for such as
difficulty with resection or image-guided ablation. Finally, recognizing
the challenges inherent to a randomized controlled trial in this setting, a
prospective evaluation of patients deemed eligible for all three treat
ment modalities and receiving counseling therein may offer insight into
oncologic outcomes with less potential for selection bias than a retro
spective evaluation.
5. Conclusions
In conclusion, for patients with solitary HCC ≤ 3 cm, the intentionto-treat survival for those receiving RFA, LR, or LT are equivalent,
with adjusted DFS of either LR or LT being better relative to RFA. Taken
into combination, the demonstrated equipoise between treatment mo
dalities supports a potential prospective trial for patients truly eligible
5
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